Literature DB >> 26169922

Pancreatic cancer: Targeting KRAS and the vitamin D receptor via microtubules.

Agnes Basseville1, Susan Bates1, Tito Fojo1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26169922     DOI： 10.1038/nrclinonc.2015.125

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

2.  Prenylation-dependent association of Ki-Ras with microtubules. Evidence for a role in subcellular trafficking.

Authors:  J A Thissen; J M Gross; K Subramanian; T Meyer; P J Casey
Journal:  J Biol Chem       Date:  1997-11-28       Impact factor: 5.157

3.  Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.

Authors:  Daniel D Von Hoff; Ramesh K Ramanathan; Mitesh J Borad; Daniel A Laheru; Lon S Smith; Tina E Wood; Ronald L Korn; Neil Desai; Vuong Trieu; Jose L Iglesias; Hui Zhang; Patrick Soon-Shiong; Tao Shi; N V Rajeshkumar; Anirban Maitra; Manuel Hidalgo
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

4.  H-ras but not K-ras traffics to the plasma membrane through the exocytic pathway.

Authors:  A Apolloni; I A Prior; M Lindsay; R G Parton; J F Hancock
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

5.  A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells.

Authors:  V Bhattacharjee; Y Zhou; T J Yen
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

6.  Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins.

Authors:  Marianne S Poruchynsky; Edina Komlodi-Pasztor; Shana Trostel; Julia Wilkerson; Marie Regairaz; Yves Pommier; Xu Zhang; Tapan Kumar Maity; Robert Robey; Mauricio Burotto; Dan Sackett; Udayan Guha; Antonio Tito Fojo
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-20       Impact factor: 11.205

7.  Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.

Authors:  Neil Desai; Vuong Trieu; Zhiwen Yao; Leslie Louie; Sherry Ci; Andrew Yang; Chunlin Tao; Tapas De; Bridget Beals; Donald Dykes; Patricia Noker; Rosie Yao; Elizabeth Labao; Michael Hawkins; Patrick Soon-Shiong
Journal:  Clin Cancer Res       Date:  2006-02-15       Impact factor: 12.531

8.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

Authors:  Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler
Journal:  N Engl J Med       Date:  2013-10-16       Impact factor: 91.245

9.  Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.

Authors:  Agnieszka K Witkiewicz; Elizabeth A McMillan; Uthra Balaji; GuemHee Baek; Wan-Chi Lin; John Mansour; Mehri Mollaee; Kay-Uwe Wagner; Prasad Koduru; Adam Yopp; Michael A Choti; Charles J Yeo; Peter McCue; Michael A White; Erik S Knudsen
Journal:  Nat Commun       Date:  2015-04-09       Impact factor: 14.919
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.